The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1369
Roflumilast (Daliresp) for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Roflumilast (Daliresp – Forest), an oral phosphodiesterase 4 (PDE4) inhibitor, was approved by the FDA to reduce the risk of exacerbations in adult patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.

STANDARD TREATMENT — The goals of drug therapy for COPD are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and decrease complications of the disease such as acute exacerbations. COPD exacerbations may hasten progression of the disease and lead to early mortality.

Patients with mild, intermittent COPD symptoms can be treated with an inhaled short-acting bronchodilator for symptom relief. When symptoms become more severe or persistent, an inhaled long-acting bronchodilator may be used. Combinations of a beta2-agonist with an anticholinergic can be used for patients inadequately ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Roflumilast (Daliresp) for COPD
Article code: 1369b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian